![Favorite pages[Japanese page]](/files/000137013.png){kind=small}
](/files/000137010.png){kind=small}
Here begins the text.
Pmda Pharmaceuticals and Medical Devices Agency
What's newBack number
January 28, 2022English Translation of Review Report: Opdivo (Partial Change Approval) and Yervoy (Partial Change Approval)
- January 28, 2022PMDA Updates (January, 2022) posted
- January 24, 2022The 41th Science Board Meeting
- January 24, 2022The 3rd Subcommittee on Therapeutic Products Based on Extracellular Vesicles (EVs) Including Exosomes
- January 21, 2022Notifications and Administrative Notices: Basic Concept on Bioequivalence Evaluation for Addition of Formulations with Different Dosage Forms in Ethical Kampo Formulations
- January 18, 2022MHLW Pharmaceuticals and Medical Devices Safety Information No.389
- January 28, 2022English Translation of Review Report: Opdivo (Partial Change Approval) and Yervoy (Partial Change Approval)
- January 21, 2022Notifications and Administrative Notices: Basic Concept on Bioequivalence Evaluation for Addition of Formulations with Different Dosage Forms in Ethical Kampo Formulations
- Currently, there is no applicable information.
- January 24, 2022The 41th Science Board Meeting
- January 24, 2022The 3rd Subcommittee on Therapeutic Products Based on Extracellular Vesicles (EVs) Including Exosomes
- January 28, 2022PMDA Updates (January, 2022) posted
